Literature DB >> 27446350

Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer.

Keith Sacco1, Aun Muhammad2, Waqar Saleem3, Heba Alshaker4, Leonardo Monzon5, Mohammad Rafiqul Islam6, Dmitri Pchejetski7.   

Abstract

Leptomeningeal metastasis (LM) is an uncommon presentation of relapse in breast cancer, which is associated with poor clinical outcomes and poor prognosis. Notably, LM most commonly occurs in breast cancer. The aim of the present review was to investigate the occurrence of LM as the primary presentation of relapse following remission in breast cancer patients and to determine whether specific histological subtypes are predisposed to meningeal metastases. In addition, the present review evaluated whether patients presenting with LM as the primary site of relapse exhibit differences in survival when compared with patients exhibiting metastasis to other sites. Cross-sectional studies have demonstrated that LM is commonly associated with other sites of distant metastasis including lung, liver and bone metastases. The histological breast cancer subtype most commonly associated with LM was invasive lobular carcinoma, while triple-negative breast cancer patients appear to be predisposed to the development of LM when considering the overall prevalence of histological breast cancer subtypes. At present, data regarding LM as the primary site of relapse are limited due to its rarity as the first site of metastasis in breast cancer. Case-controlled studies are required to investigate the incidence of LM as the primary site of recurrence in breast cancer patients as this would enable treatment standardization and identification of prognostic factors for improved survival.

Entities:  

Keywords:  breast cancer; invasive lobular cancer; leptomeningeal metastasis; triple negative breast cancer

Year:  2016        PMID: 27446350      PMCID: PMC4950696          DOI: 10.3892/ol.2016.4745

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

Review 1.  Chemotherapy in neoplastic meningitis.

Authors:  Andrea Pace; Alessandra Fabi
Journal:  Crit Rev Oncol Hematol       Date:  2006-09-01       Impact factor: 6.312

2.  Survival of breast cancer patients with meningeal carcinomatosis.

Authors:  H Gauthier; M N Guilhaume; F C Bidard; J Y Pierga; V Girre; P H Cottu; V Laurence; A Livartowski; L Mignot; V Diéras
Journal:  Ann Oncol       Date:  2010-04-29       Impact factor: 32.976

3.  Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.

Authors:  Michal Mego; Zuzana Sycova-Mila; Jana Obertova; Jan Rajec; Stefania Liskova; Patrik Palacka; Stefan Porsok; Jozef Mardiak
Journal:  Breast       Date:  2011-06-23       Impact factor: 4.380

4.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

5.  Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.

Authors:  Michael J Glantz; Alixis Van Horn; Rebecca Fisher; Marc C Chamberlain
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

6.  Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study.

Authors:  J Lamovec; A Zidar
Journal:  Arch Pathol Lab Med       Date:  1991-05       Impact factor: 5.534

7.  Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

8.  Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.

Authors:  S T Rosen; J Aisner; R W Makuch; M J Matthews; D C Ihde; M Whitacre; E J Glatstein; P H Wiernik; A S Lichter; P A Bunn
Journal:  Medicine (Baltimore)       Date:  1982-01       Impact factor: 1.889

9.  Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.

Authors:  M J Glantz; W A Hall; B F Cole; B S Chozick; C M Shannon; L Wahlberg; W Akerley; L Marin; H Choy
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

10.  Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival.

Authors:  Anna Niwińska; Halina Rudnicka; Magdalena Murawska
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

View more
  4 in total

Review 1.  Breast leptomeningeal disease: a review of current practices and updates on management.

Authors:  Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

2.  Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM).

Authors:  Anna Niwińska; Katarzyna Pogoda; Wojciech Michalski; Michał Kunkiel; Agnieszka Jagiełło-Gruszfeld
Journal:  J Neurooncol       Date:  2018-02-12       Impact factor: 4.130

Review 3.  Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review.

Authors:  Yajing Chi; Mao Shang; Liang Xu; Heyi Gong; Rongjie Tao; Lihua Song; Baoxuan Zhang; Sha Yin; Binbin Cong; Huihui Li
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

4.  Leptomeningeal Disease as an Initial Presenting Manifestation in Breast Cancer.

Authors:  Jasmine Shrestha; Asis Shrestha; Pratul Karki; Ajay Dhakal
Journal:  Cureus       Date:  2021-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.